Form 4: Twist Bioscience CAO Sells Shares for Tax Obligations

Twist Bioscience's Chief Accounting Officer, Robert F. Werner, sold 853 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Robert F. Werner, Chief Accounting Officer of Twist Bioscience Corp (TWST), reported a transaction involving the company's common stock.
• On August 25, 2025, Mr. Werner disposed of 853 shares of common stock at a price of $27.691 per share.
• This sale was a 'sell to cover' transaction, mandated by Twist Bioscience's equity incentive plans to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs).
• The transaction was not a discretionary trade by Mr. Werner.
• Following this transaction, Mr. Werner beneficially owns 48,689 shares of Twist Bioscience common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, non-discretionary transaction for tax purposes related to equity compensation, and does not reflect a positive or negative outlook on the company's performance or stock price by the insider.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The sales represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
• These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a 'sell to cover' transaction and do not represent discretionary trades by the Reporting Person.

Industry Context

This 'sell to cover' transaction is a common practice in the industry for executives who receive equity compensation, such as Restricted Stock Units (RSUs). When RSUs vest, they become taxable income, and companies often facilitate the sale of a portion of the shares to cover the associated tax liabilities. Such non-discretionary sales are generally not interpreted as a signal of management's sentiment about the company's future prospects, unlike open market discretionary sales.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in management's confidence.
• Employees: Reflects standard equity compensation and tax compliance practices for executives within the company.

Key Dates

Keywords

Twist Bioscience, TWST, Form 4, Insider Trading, Stock Sale, Chief Accounting Officer, Equity Compensation, Restricted Stock Units, Tax Withholding